Dr. Westbrook on Combatting Tumor Heterogeneity in HER2+ Breast Cancer

Kelly E. Westbrook, MD
Published: Wednesday, Oct 09, 2019



Kelly E. Westbrook, MD, assistant professor, Duke University School of Medicine, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.

Ado-trastuzumab emtansine (T-DM1; Kadcyla) is one antibody-drug conjugate currently in clinical trials with a high affinity for the HER2 receptor that treats HER2-positive cells with minimal toxicity because of low levels of T-DM1 systemically, explains Westbrook. However, it does not have the ability to target patients with low expression of HER2 cells, says Westbrook.

There are many interesting transitions in the antibody-drug conjugate world, including trying to create antibody-drug conjugates that will have an affinity for low levels of HER2 cells or a bystander effect, according to Westbrook. Traditional therapy is not affected by tumor heterogeneity because most HER2-targeted therapies are coupled with a chemotherapy backbone, which helps navigate the tumor heterogeneity, concludes Westbrook.
 
SELECTED
LANGUAGE


Kelly E. Westbrook, MD, assistant professor, Duke University School of Medicine, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.

Ado-trastuzumab emtansine (T-DM1; Kadcyla) is one antibody-drug conjugate currently in clinical trials with a high affinity for the HER2 receptor that treats HER2-positive cells with minimal toxicity because of low levels of T-DM1 systemically, explains Westbrook. However, it does not have the ability to target patients with low expression of HER2 cells, says Westbrook.

There are many interesting transitions in the antibody-drug conjugate world, including trying to create antibody-drug conjugates that will have an affinity for low levels of HER2 cells or a bystander effect, according to Westbrook. Traditional therapy is not affected by tumor heterogeneity because most HER2-targeted therapies are coupled with a chemotherapy backbone, which helps navigate the tumor heterogeneity, concludes Westbrook.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x